Other

Dekk-Tec, Inc.

Ziopharm Oncology, Inc.

Omnitron International, Inc.

Dekk-Tek, Inc.

Bo-Dekk Ventures, Ltd.

Lee Roy Morgan

Joseph H Boyer

Samuel F Liprie

Michael H Hayman

This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula 

Demethylpenclomedine analogs and their use as anti-cancer agents

A scalpel blade holder including a handle, a blunt probe, and a blade. A method of using the scalpel blade holder including inserting the blunt probe into a small incision, and advancing the scalpel blade holder to create the incision.

Scalpel blade holder

The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein Arepresents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyper-proliferative disorders, also are disclosed. 

Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents

The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula I: (I) wherein Arepresents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

The present disclosure concerns complexes of 4-hydroperoxy ifosfamide. In one embodiment the complexes can be represented by the formula wherein A represents an ammonium species selected from the conjugate acid of a basic amino acid, quaternary ammonium, aliphatic ammonium, heterocyclic ammonium, aromatic ammonium, substituted and unsubstituted pyridinium, guanidinium, and amidinium, and wherein X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents

The present disclosure relates to salts and compositions of isophosphoramide mustard and isophosphoramide mustard analogs. In one embodiment the salts can be represented by the formula wherein Arepresents an ammonium species selected from the protonated (conjugate acid) or quaternary forms of aliphatic amines and aromatic amines, including basic amino acids, heterocyclic amines, substituted and unsubstituted pyridines, guanidines and amidines; and X and Y independently represent leaving groups. Also disclosed herein are methods for making such compounds and formulating pharmaceutical compositions thereof. Methods for administering the disclosed compounds to subjects, particularly to treat hyperproliferative disorders, also are disclosed.

Salts of isophosphoramide mustard and analogs thereof as anti-tumor Agents

This disclosure concerns novel demethylpenclomedine analogs. Also disclosed are pharmaceutical compositions and methods for using such compositions to treat hyperproliferative disorders. In one embodiment the analogs are represented by the formula (1). 

A new group of fluorescent organic compounds having a variety of uses are described. They are especially useful as dye compounds in dye laser systems, and as photochemical agents in the treatment of diseased tissues using photodynamic therapy techniques. The compounds include a tri-cyclic compound having the following structure: ##STR1## Preferably R.sub.1 -R.sub.5 .dbd.R.sub.9 -R.sub.12 .dbd.C; R.sub.7 .dbd.B; R.sub.6 and R.sub.8 .dbd.N; R.sub.14 .dbd.lower n-alkyl or an electron withdrawing group such as CN.sup.- ; R.sub.16 and R.sub.19 are independently selected from the group consisting of lower n-alkyl, a sulfate or an acid or salt thereof, or hydrogen; and R.sub.20 .dbd.R.sub.21 .dbd.F. Other compounds include compounds of the formula ##STR2##

Boron difluoride compounds useful in photodynamic therapy and production

A method is disclosed for predicting response of a tumor patient to therapy, and selecting appropriate therapy for malignant neoplasms such as breast, ovarian and gastrointestinal cancer. A sample of tumor cells is cultured in the presence of 10 .mu.g/ml estradiol, and inhibition of cell growth in the culture paradoxically indicates an estrogen dependent tumor that will respond to antiestrogenic therapy. Another sample of tumor cells is cultured in the presence of a chemotherapeutic agent which predicts response of the tumor to in vivo administration of a cytotoxic agent. The chemotherapeutic agent is preferably a cytotoxic drug, or a drug having both cytotoxic and antiestrogenic mechanisms of action. A particularly suitable substance having both mechanisms of action is: ##STR1## wherein R.sup.1 H, OH, OOC(CH.sub.2).sub.2 CO.sub.2 H or CH.sub.3 COO; R.sup.2 is C.sub.6 H.sub.4 OH, C.sub.6 H.sub.4 OCOCH.sub.3, C.sub.6 H.sub.4 OOC(CH.sub.2)CO.sub.2 H, or C.sub.6 H.sub.5 ; and X is C.sub.6 H.sub.3 -2,4(NO.sub.2).sub.2, C.sub.6 H.sub.5, C.sub.6 H.sub.4 -4(NO.sub.2), C.sub.6 H.sub.4 -3(NO.sub.2), or C.sub.6 H.sub.3 -2,4(NO.sub.2).sub.2 ; Predictive power of the assay is increased by combining information from the estradiol and chemotherapeutic assays. These assays are preferably performed in culture flasks having removable bases that function as conventional microscope slides.

Method to predict tumor response to therapy

A new group of fluorescent organic materials having a variety of uses are described. They are especially useful as dye compounds in dye laser systems, and as photochemical agents in the treatment of sensitive diseased tissues using photodynamic therapy techniques. The materials involve a tri-cyclic compound such as 4,4'-difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene, the disodium salt of 4,4- difluoro-1,3,5,7,8-pentamethyl-4-bora-3a,4a-diaza-s-indacene-2,6-disulfoni c acid monohydrate, and 4,4-difluoro-1,3,5,7-tetramethyl-8-ethyl-4-bora-3a,4a-diaza-s-indacene, having the following structures: ##STR1##

Indacene compounds and methods for using the same

Apparatus for in situ radiotherapy has a flexible catheter having a proximal end for receiving a radioisotope and a distal end for positioning the flexible catheter within a patient to be treated. An anchor, which is permanently connectable to tissues deep inside the patient, has a sealing collar connected to it which seals the distal end of the catheter. The catheter also includes a plug near the distal end which seals the distal end in addititon to the seal provided by the sealing collar. The anchor has a penetration point connected to it to assist a surgeon in implanting the catheter within a tumor. A threaded fastener on the anchor is screwed into the catheter. The flexible catheter can be released remotely from the anchor by unscrewing it. A suture eye is connected to the anchor. The suture eye may be sutured to healthy tissue within the patient when the apparatus is implanted to secure the anchor to the patient. When the radioisotope is not being received, the proximal end of the catheter is sealed by a cylindrical plug connected to a manipulation handle.

Apparatus for in situ radiotherapy

Apparatus for in situ radiotherapy has a flexible catheter having a proximal end for receiving a radiosotope and a distal end for positioning the flexible catheter within a patient to be treated. An anchor, which is permanently connectable to tissues deep inside the patient, has a sealing collar connected to it which seals the distal end of the catheter. The anchor has a penetration point connected to it to assist a surgeon in implanting the catheter within a tumor. A threaded fastener is connected to the anchor and screwed into the catheter. The flexible catheter can be released remotely from the anchor by unscrewing it. A suture eye is connected to the anchor. The suture eye may be sutured to healthy tissue within the patient when the apparatus is implanted to secure the anchor to the patient.

Growing community of inventors

New Orleans, LA, United States of America

Lee Roy Morgan